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Background: Long-acting injectable antipsychotics may improve medication adherence, 
thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, 
safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched 
from oral antipsychotic medication.
Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable 
patients on oral antipsychotic medication with poor treatment adherence during the   previous 
12 months received intramuscular injections of risperidone long-acting injection (25 mg starting 
dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome 
Scale (PANSS) total score.
Results: Of the 60 patients who were screened, 53 received at least one injection (safety 
population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores 
improved significantly throughout the study and at endpoint. Significant   improvements were 
also observed in Clinical Global Impression of Severity, Personal and Social   Performance, 
and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and 
  well-tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating 
Scale was reduced significantly. The most frequently reported adverse events were insomnia 
(22.6%), increased prolactin (17.0%), and weight gain (13.2%).
Conclusion: Risperidone long-acting injection was associated with significant   symptomatic 
improvements in stable patients with schizophrenia following a switch from previous 
antipsychotic medications.
Keywords: patient compliance, adherence, risperidone, delayed-action preparations, 
schizophrenia
Introduction
Schizophrenia is a chronic mental disorder that affects approximately 1% of the 
world population and is characterized by a relapsing course with significant   burden 
for patients, families, and society.1–3 Although many patients receiving chronic 
antipsychotic therapy can be considered clinically stable, a subgroup of patients will 
eventually have poor outcomes, not achieving optimal symptom relief.4 Premature 
discontinuation and poor prescription compliance are well established reasons for sub-
optimal effectiveness in clinical practice,5–12 and 40%–50% of schizophrenic patients are 
believed to be only partially compliant.8,12 Nonadherence to oral antipsychotic therapy 
is associated with potential symptom re-emergence and a higher risk of relapse.13–18
Relapses are responsible for frequent inpatient admissions, and account for 80% of 
overall schizophrenia treatment costs.19,20 Their consequences include social and overall Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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productivity impairment, increased risk of a poor prognosis, 
and prolonged recovery in subsequent episodes.21,22 In this 
setting, alongside symptom remission, relapse prevention 
is a major therapeutic goal for schizophrenic patients. 
Atypical antipsychotics are currently a critical part of 
schizophrenia management worldwide, and several studies 
have demonstrated their efficacy and a better tolerability 
profile relative to conventional agents, with reduced risk of 
extrapyramidal side effects.23–25
Risperidone long-acting injection was the first injectable, 
long-acting, second-generation agent to become available, 
providing continuous medication delivery and reducing 
plasma level fluctuations.26,27 A robust set of evidence has 
shown that risperidone long-acting injection administered 
intramuscularly every 2 weeks improves symptom control, 
prevents relapses, positively impacts patients’ health-
related quality of life, and reduces hospitalizations.13,21,28–32 
Because compliance monitoring is a critical issue for patients 
with schizophrenia, risperidone long-acting injection can 
  potentially minimize the risk of intermittent or interrupted 
treatment, by ensuring more stable drug levels through slow 
and steady release of risperidone over several weeks.13,29,30 
Individuals with a previous history of nonadherence or 
  partial adherence are a subset of patients of special concern 
for   clinicians regarding future compliance behavior. The 
purpose of the present study was to assess the efficacy, 
safety, and tolerability of switching clinically stable patients 
with schizophrenia and a history of nonadherence on oral 
antipsychotic therapy to long-acting risperidone.
Methods
This was a 50-week, multicenter, open-label, noncomparative 
trial of risperidone long-acting injection (Risperdal Consta®; 
Janssen Pharmaceutical Companies, Johnson and Johnson, 
Sao Paolo, Brazil) in stable patients with schizophrenia 
attending seven Brazilian centers who were switched from 
oral treatment. A 50-week study duration was chosen to pro-
vide information relevant to clinical decision-making in the 
real-world setting, given that long-term follow-up is essential 
for schizophrenia patients. As required in multicenter studies, 
raters from each of the seven sites went through a training 
process on all clinical assessment scales to be used before ini-
tiating the trial. All raters were required to have prior clinical 
experience with schizophrenic patients and documented 
experience administering at least the Positive and Negative 
Syndrome Scale (PANSS), which was the primary outcome 
measure in the trial. The study was approved by the ethics 
committee at each participating site and written consent 
was obtained from each patient or their legal representative 
before enrollment.
Patients
Patients were recruited for the study if they met the follow-
ing inclusion criteria: Diagnostic and Statistical Manual of 
Mental Disorders Fourth Edition Text Revision (DSM-IV) 
criteria for schizophrenia; age 18–50 years; current treatment 
with oral antipsychotics (both first- and second-  generation); 
history of nonadherence to antipsychotic treatment within 
the previous 12 months; and PANSS # 90 and a PANSS # 4 
for conceptual disorganization, hallucinatory behavior, 
suspiciousness, and unusual thought content. Nonadherent 
patients were those fulfilling at least one of the following 
criteria: hospitalization due to interruption or irregular use 
of medication within the previous 12 months; clinical wors-
ening due to irregular use of medication; patient refusal to 
take medication, as reported by family members; difficulty 
convincing patient to accept medication, as reported by 
family members; and at least one treatment interruption 
with worsening of symptoms. Exclusion criteria included a 
history of refractoriness to antipsychotic treatment, previous 
use of clozapine, use of another depot antipsychotic within 
the previous 12 months, another major axis disorder, and risk 
of suicide. Women of childbearing age not using an approved 
method of birth control were also excluded.
study medication
Patients continued their outgoing antipsychotic for the first 
3 weeks to ensure adequate drug coverage, and the previous 
medication was interrupted thereafter. At the first study visit, 
all eligible patients were prescribed oral risperidone1 mg for 
3 days as a sensitivity and tolerability test. Patients received 
intramuscular injections of risperidone long-acting injection 
at an initial dose of 25 mg every 2 weeks. The dose could be 
increased to up to 50 mg at the investigator’s discretion. Biper-
idene for extrapyramidal symptoms and clonazepam for anxi-
ety and insomnia were allowed as concomitant medications.
Safety and efficacy measures
The primary efficacy measure was the change from baseline 
to endpoint for the total score on PANSS.33 Secondary 
efficacy measures included the change from baseline in 
PANSS subscales (negative symptoms, positive symptoms, 
general psychopathology), Clinical Global Impression 
(CGI),34 and Personal and Social Performance Scale (PSP).35 
The Drug Attitude Inventory (DAI-10) was employed to 
assess patients’ attitudes towards psychiatric medication.36Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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PSP is a 100-point classification scale that measures 
  personal and social activity in four behavioral domains 
(socially useful activities, personal and social relation-
ships, self-care, and disturbing and aggressive behaviors). 
The final scale score is obtained summing the scores of 
all four domains, and ranges from 1 to 100. The higher the 
observed score, the better the performance. DAI-10 is a 
10-item dichotomous (true or false) answer scale that enables 
classification of patients based upon their attitudes towards 
medication. A positive final total score means a positive sub-
jective response (compliant) and a negative total score means 
a negative subjective response (noncompliant). Answers are 
coded as positive (+1 point) or negative (−1 point), and the 
final score is the sum of all points.
Spontaneously reported adverse events were recorded by 
the investigator at all visits (weeks 2, 4, 8, 12, 16, 20, 24, 38, 
and 50), and severity of movement disorders was evaluated 
using the Extrapyramidal Symptom Rating Scale (ESRS).37 
Electrocardiograms and blood samples for laboratory analysis 
were obtained at screening, week 24, and endpoint.
statistical analysis
The sample size required to provide the desired 80% power 
at a two-sided alpha of 0.05 was 60 patients, considering 
the mean reduction in PANSS scores reported in two previ-
ously published clinical studies of Risperdal Consta.30,38 All 
patients who received at least one injection of risperidone 
long-acting injection and had at least one postbaseline effi-
cacy assessment (intention-to-treat population) were included 
in the efficacy analysis. The safety population comprised 
patients who received at least one injection, regardless of 
efficacy measurement status. Changes in efficacy measures 
from baseline to endpoint (week 50) were analyzed by the 
paired t-test and the Wilcoxon signed-rank test for normal 
and asymmetric continuous variables as appropriate. Scores 
measured over time (PANSS, CGI, PSP, DAI, and ESRS) were 
compared by repeated-measures analysis of variance using 
a mixed linear model for time effect (within-group factors). 
Statistical analyses were carried out using SAS® (v 9.1.3; 
SAS Institute, Cary, NC)
Results
Of the 60 patients who were screened, seven patients could 
not be enrolled in the study for the following reasons: 
injectable depot antipsychotic use within the previous 
12 months (n = 1); a clinically significant abnormality in the 
screening tests (n = 2, one electrocardiographic abnormality 
and one anemia); self-withdrawal (n = 2); and loss to 
  follow-up (n = 2, both before receiving the study medication. 
Fifty-three patients received at least one dose of   risperidone 
long-acting injection (safety population, n = 53); of these, 
two were excluded from the efficacy analysis for not undergo-
ing any postbaseline assessment (intention-to-treat   efficacy 
population, n = 51). The 50-week trial was completed 
by 29 patients (54.7%). Reasons for discontinuation are 
  presented in Figure 1. Most dropouts were due to patient’s 
request for withdrawal (62.5%); 16.7% were adverse event-
related, and none were due to lack of efficacy.
Clinical and demographic characteristics of the total sam-
ple and the subsample of study completers are summarized 
in Table 1. The study group was predominantly male (73.6%) 
with a mean age of 33.6 years. The median disease duration 
was 5.5 years (mean ± standard deviation 9.2 ± 9.9 years). 
Most patients were switched from oral risperidone (41.5%), 
followed by haloperidol (22.6%) and chlorpromazine 
(11.3%). Final doses (week 48) of risperidone long-acting 
injection were 25 mg in 38.1%, 37.5 mg in 38.1%, and 
50 mg in 23.8% of patients. Regarding concomitant medica-
tion, 15 (28.3%) patients received clonazepam, 10 (18.9%) 
received biperidene, 17 (32.1%) received risperidone, and 
14 (26.4%) received haloperidol. Haloperidol and risperidone 
were used as adjuvant antipsychotics. It was not possible to 
identify clinically relevant differences between study com-
pleters and the initial sample.
Over a 50-week period, there were significant reduc-
tions in total PANSS score and also in the PANSS positive, 
negative, and general psychopathology subscales (Table 2). 
The mean PANSS total score was significantly reduced 
from baseline to endpoint (58.8 ± 1.82 vs 49.72 ± 2.32; 
Screening
(n = 60)
ITT sample (n = 53) 
ITTs (n = 53) 
ITTe (n = 51) 
Did not complete the study (n = 24)
Adverse event (n = 4) 
Lost to follow-up (n = 2) 
Patient’s decision (n = 15) 
> 7 days delay in the application (n = 2) 
Other (n = 1) 
Completed the study
(n = 29) 
•
•
•
•
•
Figure 1 study participants.
Notes: All patients who received at least one injection of risperidone long-acting injection 
and had at least one postbaseline efficacy assessment (intention-to-treat population) 
were included in the efficacy analysis (ITTe). The safety population comprised all patients 
who received at least one injection, regardless of efficacy measurement status (ITTs).Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 1 Baseline demographic and clinical characteristics
Age (years) Total sample  
(n = 59)
Study completers 
(n = 29)
Mean (SD) 33.6 (9.1) 33.2 (10.3)
Median (range) 34 (21–57) 30 (21–57)
Gender, n (%)
Male 39 (73.6) 19 (65.5)
Female 14 (26.4) 10 (34.5)
Disease duration (years) n = 36 n = 29
Mean (SD) 9.2 (9.9) 9.9 (11.0)
Median (range) 5.5 (0–41) 5.5 (0–39)
Inpatient admissions in the last year, n (%)
Yes 11 (20.8) NA
Previous antipsychotic 
treatment, n (%)
n = 53
chlorpromazine 6(11.3) NA
haloperidol 12(22.6) NA
risperidone 22(41.5) NA
Assessments Mean (SD)
PANSS (n = 53)
Positive scale 14.1 (4.8) 13.2 (5.1)
Negative scale 18.3 (5.6) 18.5 (6.6)
Total 63.5 (14.1) 61.1 (15.7)
CGI-S (n = 53) 3.6 (0.9) 3.4 (0.8)
DAI-10 (n = 51) 2.8 (4.7) 2.2 (5.0)
Abbreviations:  PANss,  Positive  and  Negative  syndromes  scale;  DAi,  Drug 
Attitude  inventory;  cgi-s,  clinician’s  global  impression  of  Disease  severity;   
sD, standard deviation; NA, not available.
Table 2 Positive and Negative Syndromes Scale measures (n = 51)
Week Positive scale  
mean (SE)
Negative scale  
mean (SE)
General psychopathology  
scale mean (SE)
Total scale  
mean (SE)
0 12.61 (0.60) 16.69 (0.68)* 29.51 (0.97) 58.80 (1.82)
2 12.41 (0.60) 15.49 (0.68)** 27.63 (0.97)* 55.53 (1.82)*
4 12.06 (0.60)* 15.25 (0.69)** 26.51 (0.98)** 53.82 (1.83)**
8 11.00 (0.61)* 14.13 (0.69)** 26.14 (1.00)** 51.28 (1.86)**
16 10.90 (0.65)* 13.87 (0.72)** 25.77 (1.07)** 50.55 (1.98)**
24 10.01 (0.69)** 13.56 (0.75)** 25.33 (1.16)** 48.95 (2.13)**
38 10.37 (0.73)** 13.22 (0.78)** 23.82 (1.24)** 47.40 (2.26)**
50 10.87 (0.75)* 13.40 (0.79)** 25.47 (1.28)** 49.72 (2.32)**
Fixed effects test (week) P = 0.0009 P , 0.0001 P = 0.0017 P , 0.0001
Notes: *P , 0.05 vs week 0; **P , 0.01 vs week 0.
Abbreviation: se, standard error of the mean.
P = 0.0002). A significant improvement was seen at week 
4, and this effect was maintained throughout the study. In 
addition, significant improvements were observed from 
baseline to endpoint and during the study in all PANSS 
subscales.
Mean CGI also significantly improved from baseline to 
endpoint (mean ± standard error of the mean = 3.55 ± 0.13 
vs 3.19 ± 0.16; P = 0.0131). The factor “week of   treatment” 
had a statistically significant effect from week 4   (P , 0.01) 
and these clinical benefits remained stable until the final 
visit (Table 3). For the PSP scale, the time factor also had 
a positive impact on mean performance scores, which 
improved from 60.0 (95% confidence interval [CI]: 
54.2–65.7) at baseline to 69.1 (95% CI: 64.8–73.4) at week 
50 (P = 0.0002, Table 3).
DAI-10 scores were measured at four different visits 
from baseline to endpoint. At all visits, significant improve-
ments were observed and the mean (± standard error of 
the mean) scores rose from 2.78 ± 0.68 to 5.07 ± 0.77 
(P = 0.0062). There was a progressive and sustained increase 
in DAI-10 scores, showing positive attitudes towards 
risperidone long-acting injection throughout the study, as 
shown in Table 3.
Adverse events were reported by 40 (75.5%) patients. 
Adverse events reported in more than 10% of patients were 
insomnia (22.6%), increased prolactin levels (17.0%), and 
weight gain (13.2%). Investigators categorized 22 (41.5%) 
adverse events as likely or very likely related to the study 
drug (Table 4). Three serious adverse events were reported 
by the investigators, ie, psychomotor agitation, worsen-
ing of symptoms, and worsening of psychotic symptoms. 
There were three (5.7%) early discontinuations due to 
adverse events (sexual dysfunction, decreased libido, 
psychomotor agitation, and worsening of pre-existing 
symptoms).
Severity of movement disorders was significantly reduced 
during treatment with risperidone long-acting injection 
(Table 5). Significant improvements were noted on the ESRS 
overall scale, subjective evaluation, and extrapyramidal 
symptoms item from week 4 (P , 0.0001). Changes in 
laboratory findings other than serum prolactin were not 
clinically significant, although high-density lipoprotein 
and creatinine changes reached statistical significance 
(Table 6). The 29 patients for whom weight data at baseline 
and endpoint were available showed a mean weight gain of 
2.8 ± 4.6 kg (P , 0.001).Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 4 Frequency of adverse events during the study period 
(efficacy population)
Adverse events reported by $5% of patients, n (%) n = 53
insomnia 12 (22.6)
increased prolactin 9 (17.0)
Weight gain 7 (13.2)
Anxiety 3 (5.7)
epigastralgia 3 (5.7)
reduced appetite 3 (5.7)
Adverse events related to the study drug, n (%) n = 53
increased prolactin 9 (17.0)
Weight gain 5 (9.4)
Table 5 Extrapyramidal Symptom Rating Scale (n = 50)
Week ESRS (total score)
Mean
0 0.46 (0.07)
2 0.416 (0.07)*
4 0.272 (0.07)*
8 0.289 (0.07)**
16 0.271 (0.08)**
24 0.221 (0.08)**
50 0.089 (0.08)**
Notes: Test of fixed effects (week) of the adjusted model: P , 0.0001; *P , 0.01 
vs baseline.
Abbreviation: esrs, extrapyramidal symptom rating scale.
Discussion
The findings of this open-label study demonstrate that ris-
peridone long-acting injection was an effective treatment in a 
real-world setting for clinically stable Brazilian patients with 
schizophrenia who were switched from other antipsychotic 
agents due to poor compliance, as assessed by change in 
scores on PANSS measures and CGI-S. Patients achieved sig-
nificant clinical improvements in terms of symptom control 
when switched directly to risperidone long-acting injection 
from their current antipsychotic therapy. Most patients main-
tained the lower doses of risperidone long-acting injection, ie, 
25 mg and 37.5 mg, during the trial. The mean PANSS total 
score was significantly reduced from baseline to endpoint, 
and patients remained stable, not showing any worsening of 
symptoms. Most clinical improvement was apparent in the 
first month after switching. Results from a number of other 
clinical studies have also reported significant and sustained 
clinical improvement in patients directly switched to risperi-
done long-acting injection from their previous antipsychotic 
agents.29,38,39
In a 12-week, randomized, placebo-controlled trial by 
Kane et al, risperidone long-acting injection was associ-
ated with significantly greater improvements in PANSS 
and CGI-S scores at endpoint compared with placebo.30 
  Significant improvements in total PANSS scores (P , 0.01), 
positive symptoms (P , 0.01), and negative symptoms 
(P , 0.001) were also observed during an international, 
open-label, 12-month study conducted by Fleischhacker 
et al in patients with schizophrenia who were switched to 
risperidone long-acting injection from oral or long-acting 
conventional or oral atypical antipsychotics.29
Risperidone long-acting injection was well-tolerated, with 
minimal weight change and an overall favorable safety profile. 
ESRS score showed minimum change between baseline and 
endpoint. Although of minimum magnitude in clinical terms, 
the statistically significant change in high-density lipoprotein 
could potentially raise concern about metabolic side effects. 
However, the observed decrease was not accompanied 
by consistent changes in total cholesterol, low-density 
lipoprotein, very low-density lipoprotein, triglycerides, and 
fasting glycemia, reinforcing the absence of clinically sound 
metabolic effects of risperidone long-acting injection in 
Table  3  clinician’s  global  impression  of  Disease  severity 
(n = 51), Personal and Social Performance (n = 34), and Drug 
Attitude Inventory-10 (n = 51) measures
Week CGI –S
Mean (SE)
0 3.55 (0.13)
2 3.37 (0.13)*
4 3.30 (0.13)**
8 3.21 (0.13)**
16 3.10 (0.14)**
24 2.92 (0.15)**
38 2.94 (0.15)**
50 3.19 (0.16)*
Test of fixed effects (week) of the adjusted model: P , 0.0001.
Week PSP scale
Mean (SE)
Baseline (n = 10) 60.0 (2.9)
8 (n = 17) 66.4 (2.4)*
16 (n = 19) 72.6 (2.3)**
24 (n = 29) 71.7 (2.1)**
38 (n = 29) 71.8 (2.1)**
50 (n = 26) 69.1 (2.2)**
Test of fixed effects (week) of the adjusted model: P = 0.0002.
Week DAI-10
Mean (SE)
Baseline 2.78 (0.62)
8 4.45 (0.64)*
24 4.59 (0.69)*
50 5.07 (0.77)**
Notes: Test of fixed effects (week) of the adjusted model: P , 0.0001; *P , 0.05 vs 
baseline; **P , 0.01 vs baseline.
Abbreviations:  DAi-10,  Drug  Attitude  inventory;  cgi-s,  clinician’s  global 
impression  of  Disease  severity;  PsP,  Personal  and  social  Performance  scale;   
se, standard error of the mean.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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this sample. The creatinine increase, although statistically 
significant, was considered clinically irrelevant.
The incidence of adverse events was comparable with 
those reported in previous studies. According to the report 
by Kane et al, risperidone long-acting injection was generally 
well-tolerated, with an overall incidence of adverse events 
similar to that with placebo in comparative trials.30 In that 
study, similar proportions of patients reported adverse events 
in the active and control group, while serious adverse events 
were more frequent in the placebo group (23.5%) than in 
the 25, 50, and 75 mg risperidone long-acting injection 
groups (13%, 14%, and 15%, respectively).30 Results from 
other studies have also reported that patients can be safely 
switched from oral conventional or atypical therapy and 
conventional long-acting agents to risperidone long-acting 
injection.38,40–42
These findings confirm the effectiveness of switching 
stable patients with schizophrenia from other antipsy-
chotics to risperidone long-acting injection in a Brazilian 
real-world setting. Following a switch to risperidone long-
acting injection, stable patients showed further significant 
improvements in symptom control over the treatment 
period, reducing their PANSS total score and subscales 
and CGI-S scores.
Some of the limitations of the study were its small 
sample size, a relatively high dropout rate (42.5%), and the 
open-label design. In absolute terms, the observed dropout 
rate was not significantly greater in magnitude than that 
observed in previous atypical antipsychotic trials (33.5% 
in fixed-dose studies and 45.0% in flexible-dose studies).43 
This study enrolled only patients with a previous history of 
compliance issues, which could also be a factor explaining 
the higher dropout rates, especially those due to patient 
request. Subgroup analysis according to study completion 
status was not performed.
Another limitation is the lack of inter-rater reliability 
assessments as part of the trial. Rater training was performed 
to improve raters’ clinical skills and to ensure standardized 
clinical assessments before the study initiation, but statisti-
cal evaluation of inter-rater reliability was not conducted. 
Nevertheless, this study yielded useful knowledge on the 
effectiveness and safety of risperidone long-acting injection 
in a Brazilian population over a 12-month study period, and 
observed significant clinical improvements after switching 
from oral antipsychotics to risperidone long-acting injection. 
These findings justify further comparative studies addressing 
differences in terms of relapse prevention.
Conclusion
Long-acting injectable risperidone is an effective and safe 
treatment alternative for patients with schizophrenia and 
a history of poor adherence to oral treatment. The study 
indicates a favorable tolerability profile, a positive effect 
on personal and social functioning, and adequate patient 
treatment acceptance. These findings reinforce long-
acting injectable risperidone as a reasonable alternative for 
long-term care of stable schizophrenia patients in whom 
compliance issues are anticipated.
Table 6 Laboratory parameters at baseline and at final evaluation (on week 50 or at the patient’s last evaluation in case of early 
withdrawal from the study)
Laboratory parameters Evaluation Mean (SD) Minimum Maximum P value
Total cholesterol (mg/dL) Baseline 172.9 (34.5) 112 279 0.758
Final 171.7 (33.2) 106 233
HDL (mg/dL) Baseline 45.6 (13.1) 27 78 0.044
Final 43.5 (13.5) 24 76
LDL (mg/dL) Baseline 99.6 (28.8) 32 184
Final 97.0 (29.3) 24 163 0.384
VLDL (mg/dL) Baseline 23.1 (11.6) 9 62
Final 27.1 (14.4) 7 73 0.074
Creatinine (mg/dL) Baseline 0.86 (0.17) 0.40 1.10
Final 0.96 (0.18) 0.56 1.28 0.005
Fasting glycemia (mg/dL) Baseline 92.1 (25.6) 75 249
Final 92.0 (10.9) 57 114 0.153
Prolactin (ng/mL) Baseline 36.2 (40.1) 2.1 181.0
Final 49.9 (43.6) 4.1 232.4 0.006
Triglycerides (mg/dL) Baseline 112.5 (62.0) 42.0 313.0
Final 123.8 (71.7) 36.0 367.0 0.201
Abbreviations: sD, standard deviation; hDL, high-density lipoprotein LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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